Lundbeck

Lundbeck is a global pharmaceutical company specialized in brain diseases.

Launch date

Jan 1915

Employees

5001-10000 people

Market cap

Enterprise valuation

€5.3b (Public information from Sep 2024)

Copenhagen Capital Region of Denmark (HQ)

http://lundbeck.com

https://twitter.com/lundbeck https://www.linkedin.com/company/lundbeck

View job openings

Corporate Venture Fund: Lundbeckfonden Ventures

Revenues, earnings & profits over time

DKK	2020	2021	2022	2023	2024	2025	2026
Revenues	17.7b	16.3b	18.2b	19.9b	21.8b	22.9b	24.1b
% growth	4 %	(8 %)	12 %	9 %	9 %	5 %	5 %
EBITDA	4.8b	3.7b	4.7b	5.7b	6.2b	6.7b	7.2b
% EBITDA margin	27 %	23 %	26 %	28 %	29 %	29 %	30 %
Profit	1.6b	1.3b	1.9b	2.3b	3.2b	3.6b	4.1b
% profit margin	9 %	8 %	11 %	12 %	15 %	16 %	17 %
EV / revenue	-	-	1.5x	1.6x	1.9x	1.6x	1.4x
EV / EBITDA	-	-	5.9x	5.5x	6.7x	5.7x	4.7x

Date	Investors	Amount	Round
Oct 2000	N/A	N/A	IPO
Mar 2020	Michael J. Fox Foundation for Parkinson's Research	N/A	Grant
Total Funding		-

Tech stackLearn more about the technologies and tools that this company uses.

By Country

United States 4 United Kingdom 2 Denmark 1 Netherlands 1

By Industry

By Round

ACQUISITION 5 LATE VC 2 SERIES C 1

Abide Therapeutics

ACQUISITION by Lundbeck May 2019

ACQUISITION by Allergan Jul 2015

Ovation Pharmaceuticals

ACQUISITION by Lundbeck Mar 2009

Alder Biopharmaceuticals

ACQUISITION by Lundbeck Sep 2019

Chelsea Therapeutics International

ACQUISITION by Lundbeck May 2014

exited

Prexton therapeutics

ACQUISITION by Lundbeck Mar 2018